Integrated multi-omics analysis reveals osteokines involved in global regulation
Ontology highlight
ABSTRACT:
ORGANISM(S): Mus Musculus
SUBMITTER: 
Xiaochun Bai
PROVIDER: PXD048706 | iProX | Fri Jan 19 00:00:00 GMT 2024
REPOSITORIES: iProX
Similar Datasets
Project description:During aging, senescent cells accumulate in bone marrow and secrete the dysfunctional factors, termed senescence associated secretory phenotype (SASP), which is implied to regulate bone metabolism. To identify the key SASP factors in bone marrow that influence skeletal aging, we analyzed the dysregulated factors in the bone marrow supernatant from young and aged rat through mass spectrometry. In another hand, BMSCs treated with rGCA, transfection of siRNA-Plxnb2 or controls were subjected to global quantitative phosphoproteomic analysis.
2023-02-28 | PXD027548 | Pride
Project description:Proctor2016 - Circadian rhythm of PTH and the
dynamics of signaling molecules on bone remodeling
This model is described in the article:
Simulated Interventions to
Ameliorate Age-Related Bone Loss Indicate the Importance of
Timing.
Proctor CJ, Gartland A.
Front Endocrinol (Lausanne) 2016; 7:
61
Abstract:
Bone remodeling is the continuous process of bone resorption
by osteoclasts and bone formation by osteoblasts, in order to
maintain homeostasis. The activity of osteoclasts and
osteoblasts is regulated by a network of signaling pathways,
including Wnt, parathyroid hormone (PTH), RANK
ligand/osteoprotegrin, and TGF-?, in response to stimuli, such
as mechanical loading. During aging there is a gradual loss of
bone mass due to dysregulation of signaling pathways. This may
be due to a decline in physical activity with age and/or
changes in hormones and other signaling molecules. In
particular, hormones, such as PTH, have a circadian rhythm,
which may be disrupted in aging. Due to the complexity of the
molecular and cellular networks involved in bone remodeling,
several mathematical models have been proposed to aid
understanding of the processes involved. However, to date,
there are no models, which explicitly consider the effects of
mechanical loading, the circadian rhythm of PTH, and the
dynamics of signaling molecules on bone remodeling. Therefore,
we have constructed a network model of the system using a
modular approach, which will allow further modifications as
required in future research. The model was used to simulate the
effects of mechanical loading and also the effects of different
interventions, such as continuous or intermittent
administration of PTH. Our model predicts that the absence of
regular mechanical loading and/or an impaired PTH circadian
rhythm leads to a gradual decrease in bone mass over time,
which can be restored by simulated interventions and that the
effectiveness of some interventions may depend on their
timing.
This model is hosted on
BioModels Database
and identified by:
BIOMD0000000612.
To cite BioModels Database, please use:
BioModels Database:
An enhanced, curated and annotated resource for published
quantitative kinetic models.
To the extent possible under law, all copyright and related or
neighbouring rights to this encoded model have been dedicated to
the public domain worldwide. Please refer to
CC0
Public Domain Dedication for more information.
2024-09-02 | BIOMD0000000612 | BioModels
Project description:Aging causes dysfunctional changes to the bone microenvironment that lead to osteoporosis development. Osteoporosis is a serious bone health issue that is characterized by decreased bone formation and increased bone resorption. The aim of this study is to evaluate the effects of natural compounds, Apigenin and Rutaecarpine on osteoblast differentiation and examine if Apigenin and Rutaecarpine can rescue osteogenesis in aging-context. Using human bone marrow stromal cell line (hBMSCs) and primary cells obtained from young and aged women, we showed that Apigenin and Rutaecarpine are potent in inducing osteoblast differentiation and mineralization. These compounds were able to reduce senescence along with their impacts on suppressing oxidative stress and inflammation, which both contribute to aging and bone metabolic dysfunctions. Our microarray-based transcription profiling of hBMSC-derived osteoblasts treated with either 1 µM of Apigenin or Rutaecarpine during osteoblast differentiation for 21 days revealed distinct impacts of Apigenin and Rutaecarpine on different genes including those involved in bone metabolism and skeletal system development. Additionally, Ex-vivo organotypic embryonic chick-femur culture model was used to determine the osteogenic effects of Apigenin and Rutaecarpine. The average bone volume and cortical thickness of these chick femurs were both increased significantly by Apigenin and Rutaecarpine. Collectively, our study provides a novel insight for developing therapeutic strategies using natural compounds to combat aging and its effect on bone health.
2024-03-20 | GSE252845 | GEO
Project description:Global expression profile of human osteoblast treated with chemotherapy-treated bone marrow stromal cell conditioned media, compared to human osteoblast cells treated with diluent-control bone marrow stromal cell conditioned media. Goal is to identify genes regulated by chemotherapy in osteoblasts.
2010-09-30 | GSE17842 | GEO
Project description:Purpose: We have used microarrays to identify gene expression profiles that distinguish mouse OS cells from normal pre-osteoblast cells and mature osteoblast cells. Methods: Transcriptional profiles of three cell lines derived from tumors from Osx-Cre p53fl/fl Rbfl/fl (fibroblastic OS) mouse model, and from pre-osteoblast cells (Kusa4b10 mouse bone marrow stromal cell line) and osteoblast cells (derived by in vitro differentiation of the Kusab410 mouse bone marrow stromal cell line) were generated by microarray analysis, each in triplicate, using Affymetrix mouse Gene1.0ST arrays. Transcriptional profiles were analyzed in cell lines derived from tumors from a genetically engineered mouse model of human osteosarcoma (Osx-Cre p53fl/fl Rbfl/fl) and osteoblast cells derived from the Kusa4b10 mouse bone marrow stromal cell line, in the undifferentiated state (pre-osteoblasts) and differentiated state (osteoblasts).
2015-01-29 | E-GEOD-63939 | biostudies-arrayexpress
Project description:Purpose: We have used microarrays to identify gene expression profiles that distinguish mouse OS cells from normal pre-osteoblast cells and mature osteoblast cells. Methods: Transcriptional profiles of three cell lines derived from tumors from Osx-Cre p53fl/fl Rbfl/fl (fibroblastic OS) mouse model, and from pre-osteoblast cells (Kusa4b10 mouse bone marrow stromal cell line) and osteoblast cells (derived by in vitro differentiation of the Kusab410 mouse bone marrow stromal cell line) were generated by microarray analysis, each in triplicate, using Affymetrix mouse Gene1.0ST arrays.
2015-01-29 | GSE63939 | GEO
Project description:Purpose: Identification of relevant genetic pathways that are altered with aging knowing that the precursors for bone-forming osteoblasts reside in the mesenchymal cell population of bone marrow. Method: harvested and characterized, without in vitro culture, mesenchymal cells form human bone marrow capable of osteogenic differentiation Results: Identification of differentially regulated genes with aging in a highly enriched human bone marrow mesenchymal cell population. Conclusions: we have for the first time identified age-related differential gene expression and DNA methylation patterns in a highly enriched human bone marrow mesenchymal cell populationprofiles. Our results show that NGS offers a comprehensive and more accurate quantitative and qualitative evaluation of mRNA content within a cell or tissue. We conclude that RNA-seq based transcriptome characterization would expedite genetic network analyses and permit the dissection of complex biologic functions.
2017-02-10 | GSE94736 | GEO
Project description:This SuperSeries is composed of the following subset Series: GSE17839: Human osteoblast treated with Melphalen GSE17842: Human osteoblast treated with chemotherapy-treated bone marrow stromal cell conditioned media GSE17843: Human osteoblast treated with recombinant TGF-beta Refer to individual Series
2010-09-30 | E-GEOD-17860 | biostudies-arrayexpress
Project description:Osteoblast lineage cells within adult bone marrow are exposed to varying oxygen levels. Hypoxia-Inducible Factor-1α (HIF1α) and HIF2α are pivotal in the cellular response to hypoxia. Our study explores the effects of targeted HIF2α deletion in mesenchymal progenitors and their descendants. We demonstrate that HIF2α acts as a negative regulator of osteoblastogenesis and bone mass accrual. Therapeutically targeting HIF2α could be beneficial in treating low bone mass conditions, such as those observed in chronic diseases, osteoporosis, or during aging. To elucidate the mechanisms underlying the increased bone mass resulting from HIF2α loss, we performed single-cell RNA sequencing (scRNA-seq) on bone marrow stromal cells from both mutant mice lacking HIF2α in PRX1 lineage cells and control mice.
2024-11-12 | GSE263228 | GEO
Project description:Global expression profile of human osteoblast treated with chemotherapy-treated bone marrow stromal cell conditioned media, compared to human osteoblast cells treated with diluent-control bone marrow stromal cell conditioned media. Goal is to identify genes regulated by chemotherapy in osteoblasts. Dye-swap design with 6 biological replicates. Three arrays performed with chemotherapy treated samples on channel 1 and diluent-control treated on channel 2; three arrays performed with chemotherapy treated samples on channel 2 and diluent-control on channel 1.
2010-09-30 | E-GEOD-17842 | biostudies-arrayexpress